COMP <GO>
ICUI vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
ICU Medical Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ICUI 1
— ABBV 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $168.65 (+1.36%) • MKT CAP: $4.22B
roic
1.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICUI VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICUI | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.80% | 70.20% | -33.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 1.00% | 29.00% | -28.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 46.6x | 33.3x | +13.30 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 2.18% | 3.47% | -1.29 | ABBV | /fcf-yield <GO> |
| Operating Margin | 1.90% | 24.60% | -22.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 6.90% | -6.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -6.30% | 8.60% | -14.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ICUI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 65.1 | -15.03 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.22B | $513.86B | -$509.64B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICUI REV | ABBV REV | ICUI GROSS % | ABBV GROSS % | ICUI FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.23B | $61.16B | 36.8% | 70.2% | $91.8M | $17.82B |
| FY 2024 | $2.38B | $56.33B | 34.6% | 70.0% | $124.7M | $17.83B |
| FY 2023 | $2.26B | $54.32B | — | — | $166.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICUI // BETA —
ABBV // BETA 1.15